Drug Guidance
Omalizumab biosimilar for treating inflammatory conditions
Condition
Blood and Immune System
Respiratory
6 February 2026
-
Published on 06 February 2026
Last Updated on 06 February 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes for listing on the MOH Standard Drug List (SDL). The decision was based on acceptable clinical and cost effectiveness.
Funding Status
SDL subsidy will apply from 1 April 2026 to all registered indications of omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes in Singapore.
SDL subsidy does not apply to other brand(s), formulation(s) or strength(s) of omalizumab.
Guidance_Omalizumab biosimilar for treating inflammatory conditions (6 Feb 2026)